Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to...
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a...
State Grid Jinchang Power Supply Company Launches "Warm Winter" Power Security Campaign to Safeguard Stable Operation of 26 Heating Stations
JINCHANG, China, Oct. 29, 2025 /PRNewswire/ -- As the heating season approaches, State Grid Jinchang Power Supply Company has recently fully launched a special power security campaign covering heating stations across the city. Through proactive...